triptorelin pamoate - Profile

What are the generic drug sources for triptorelin pamoate and what is the scope of freedom to operate?

Triptorelin pamoate is the generic ingredient in two branded drugs marketed by Azurity and Verity, and is included in four NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Triptorelin pamoate has forty-seven patent family members in thirty-two countries.

Summary for triptorelin pamoate

International Patents:	47
US Patents:	1
Tradenames:	2
Applicants:	2
NDAs:	4

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for triptorelin pamoate

Dosage:

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage:

INJECTABLE;INTRAMUSCULAR

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for triptorelin pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	TRIPTODUR KIT	triptorelin pamoate	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	208956-001	Jun 29, 2017		RX	Yes	Yes			Y
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001		RX	Yes	Yes
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010		RX	Yes	Yes			Y

Expired US Patents for triptorelin pamoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	022437-001	Mar 10, 2010
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	021288-001	Jun 29, 2001
Verity	TRELSTAR	triptorelin pamoate	INJECTABLE;INTRAMUSCULAR	020715-001	Jun 15, 2000

International Patents for triptorelin pamoate

Country	Patent Number	Title	Estimated Expiration
Serbia	58248	FARMACEUTSKA KOMPOZICIJA SA SPORIM OSLOBAĐANJEM PRIPREMLJENA OD MIKROČESTICA (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES)
Tunisia	2009000476	SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES
South Korea	20100023950	SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES
Malaysia	150450	SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES
Eurasian Patent Organization	019284	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ПРОЛОНГИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, ПРИГОТОВЛЕННАЯ ИЗ МИКРОЧАСТИЦ (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES)
Denmark	2164467

Investment and Fundamentals Analysis of Triptorelin Pamoate

Last updated: February 20, 2026

What is Triptorelin Pamoate?

Triptorelin pamoate is a long-acting gonadotropin-releasing hormone (GnRH) agonist. It is primarily used for hormone-dependent cancers such as prostate cancer, endometriosis, and in assisted reproductive technology (ART) protocols. The compound functions by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which reduces testosterone and estrogen levels.

Market Overview and Growth Drivers

Market Size and Segments

• The global GnRH agonists market was valued at approximately USD 3.4 billion in 2021.
• Triptorelin products hold a significant share, especially in prostate cancer and endometriosis treatment.
• Major competitors include Ferring Pharmaceuticals (Diphereline/Decapeptyl), Ipsen (Sermorelin), and Sun Pharmaceutical (Triptorelin formulations).

Key Growth Drivers

• Rising incidence of hormone-dependent cancers: prostate and breast cancer.
• Increased adoption of ART techniques requiring GnRH analogs.
• Expansion in emerging markets due to increased healthcare infrastructure.
• Patent expirations of existing products, opening markets for generics.

Market Challenges

• Patent cliffs for leading brands.
• Regulatory hurdles in different regions.
• Competition from alternative therapies and biosimilars.

Patent and Regulatory Landscape

Patent Status

• Original patents for triptorelin formulations expired in key markets around 2015-2018.
• Multiple generics have entered markets since then.
• Proprietary formulations or delivery systems may still be under patent protection.

Regulatory Approvals

• Approved by FDA (2019), EMA (2010), and other agencies for various indications.
• Post-approval, regulatory pathways for biosimilars and generics are streamlined, reducing time to market.

Production and Supply Chain Considerations

• Triptorelin is a peptide synthesized via solid-phase peptide synthesis (SPPS).
• Manufacturing complexity affects the cost structure and entry barriers.
• Supply chain stability depends on peptide raw materials, peptide synthesis capacity, and sterile formulation facilities.

Competitive Landscape and R&D Prospects

• Ferring and Ipsen dominate patent-protected markets.
• Several companies are developing oral formulations and novel drug delivery systems.
• Investments in sustained-release formulations could extend product lifecycle and market share.

Investment Fundamentals

Revenue Potential

• Annual sales for existing triptorelin products exceed USD 1 billion worldwide.
• Growth avenues include combination therapies and expanded indications such as infertility.

Cost Structure

• High manufacturing costs due to peptide synthesis and sterile processing.
• R&D costs are significant for new formulation development but lower for generic production.

Regulatory and Market Entry Barriers

• Patent expirations facilitate entry.
• Regulatory pathways are well-established, with fast approval for generics/biosimilars.
• Scale-up requirements for manufacturing provide a barrier for smaller entrants.

Pricing Dynamics

• Prices declined post-patent expiries but stabilized with the introduction of generics.
• Premium prices remain for proprietary formulations or novel delivery systems.

Strategic Considerations for Investors

• Entering the market through generic or biosimilar product development offers high-volume, lower-margin opportunities.
• Innovation, such as sustained-release formulations, could fetch higher margins.
• Partnerships with contract manufacturing organizations (CMOs) improve supply chain resilience.

Key Risks

• Regulatory delays or rejections.
• Market saturation due to generic competition.
• Pricing pressures in mature markets.
• Development of alternative therapies reducing demand.

Conclusion

Triptorelin pamoate presents an established market with significant revenue streams. Post-patent expiration, opportunities shift toward generics and new formulations. Firms with manufacturing expertise and efficient Regulatory strategies can capitalize on growth in emerging markets and new therapeutic applications. However, competitive intensity and price erosion pose persistent risks.

---

Key Takeaways

• The global GnRH agonist market is large and mature, with triptorelin products commanding a significant share.
• Patent expiries have increased generic competition, pressuring prices but also expanding market access.
• Development of new formulations and indications can extend product lifecycle and profitability.
• Manufacturing complexity creates barriers to entry, favoring established players.
• Strategic partnerships and innovation are critical for maintaining competitiveness.

---

FAQs

How does patent expiry influence triptorelin market dynamics?

Patent expiry opens the market to generics, reducing prices and increasing accessibility but diminishes the revenue of original brands.

What are the primary indications for triptorelin?

Prostate cancer, endometriosis, precocious puberty, and used in ART protocols.

Are biosimilars viable for triptorelin?

Yes, biosimilar development is feasible as peptide therapeutics qualify under biosimilar pathways, providing cost-effective alternatives.

What are prospects for new formulations?

Extended-release formulations and oral versions are under development, potentially offering higher margins and improving patient compliance.

Who are the main competitors?

Ferring Pharmaceuticals, Ipsen, Sun Pharmaceutical, and several regional generic manufacturers.

---

References

[1] MarketsandMarkets. (2022). GnRH agonists market by product, application, and region.
[2] U.S. Food and Drug Administration. (2019). Triptorelin (Brand: Decapeptyl).
[3] European Medicines Agency. (2010). Summary of Product Characteristics: Decapeptyl.
[4] Ferring Pharmaceuticals. (2022). Product information for Diphereline (triptorelin).
[5] GlobalData. (2022). Peptide Therapeutics Market Size and Trends.